267 related articles for article (PubMed ID: 35072634)
41. Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.
Zhang L; Coffin J; Formenti K; Chu Q; Izevbaye I
BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35091437
[TBL] [Abstract][Full Text] [Related]
42. Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.
Fukui T; Tachihara M; Nagano T; Kobayashi K
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267492
[TBL] [Abstract][Full Text] [Related]
43. Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis.
Hao KJ; Jia X; Dai WT; Huo ZM; Zhang HQ; Liu JW; Wang XB
Front Oncol; 2021; 11():689553. PubMed ID: 35047380
[TBL] [Abstract][Full Text] [Related]
44. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
45. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
46. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
47. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
48. The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature.
Alzoubi A; Shirazi H; Alrawashdeh A; Al-Dekah AM; Ibraheem N; Kheirallah KA
Pharmaceutics; 2024 Jan; 16(2):. PubMed ID: 38399228
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.
Fang Y; Wang Y; Zeng D; Zhi S; Shu T; Huang N; Zheng S; Wu J; Liu Y; Huang G; Xue Y; Bin J; Liao Y; Shi M; Liao W
Oncoimmunology; 2021; 10(1):1951019. PubMed ID: 34345533
[TBL] [Abstract][Full Text] [Related]
50. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
51. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
52. Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F; Kim A; Khoury JH; Kota VK
J Clin Med; 2020 May; 9(5):. PubMed ID: 32443762
[TBL] [Abstract][Full Text] [Related]
53. Mapping the knowledge domain of the evolution of emergy theory: a bibliometric approach.
Xu X; Feng C
Environ Sci Pollut Res Int; 2021 Aug; 28(32):43114-43142. PubMed ID: 34152539
[TBL] [Abstract][Full Text] [Related]
54. Bibliometric analysis of research hotspots and development trends in selective fetal reduction.
Meng YL; Ren LJ; Yin SW
J Obstet Gynaecol Res; 2021 May; 47(5):1694-1703. PubMed ID: 33634542
[TBL] [Abstract][Full Text] [Related]
55. Emerging Trends and Thematic Evolution of Breast Cancer: Knowledge Mapping and Co-Word Analysis.
Sadatmoosavi A; Tajedini O; Esmaeili O; Abolhasani Zadeh F; Khazaneha M
JMIR Cancer; 2021 Oct; 7(4):e26691. PubMed ID: 34709188
[TBL] [Abstract][Full Text] [Related]
56. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
57. Trends and Developments in the Detection of Pathogens in Central Nervous System Infections: A Bibliometric Study.
Guo Y; Yang Y; Xu M; Shi G; Zhou J; Zhang J; Li H
Front Cell Infect Microbiol; 2022; 12():856845. PubMed ID: 35573778
[TBL] [Abstract][Full Text] [Related]
58. Emergence of a
Minari R; Gnetti L; Lagrasta CA; Squadrilli A; Bordi P; Azzoni C; Bottarelli L; Cosenza A; Ferri L; Caruso G; Silini EM; Tiseo M
Transl Lung Cancer Res; 2020 Jun; 9(3):787-792. PubMed ID: 32676339
[TBL] [Abstract][Full Text] [Related]
59. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.
Dhawan A; Nichol D; Kinose F; Abazeed ME; Marusyk A; Haura EB; Scott JG
Sci Rep; 2017 Apr; 7(1):1232. PubMed ID: 28450729
[TBL] [Abstract][Full Text] [Related]
60. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
